Inhibikase Therapeutics, INC. (IKT) — DEF 14A Filings

All DEF 14A filings from Inhibikase Therapeutics, INC.. Browse 4 Proxy Statement reports with AI-powered summaries and risk analysis.

DEF 14A Filings (4)

Inhibikase Therapeutics Files 2025 Proxy Statement — May 12, 2025 Risk: low
Inhibikase Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on May 12, 2025, for its annual meeting on June 27, 2025. The filing concerns the s
Inhibikase Therapeutics Files 2025 Proxy Statement — Nov 18, 2024 Risk: medium
Inhibikase Therapeutics, Inc. filed its definitive proxy statement on November 18, 2024, for its 2025 annual meeting of stockholders, which is scheduled for Jan
Inhibikase Therapeutics Files Definitive Proxy Statement — Jun 20, 2024 Risk: low
Inhibikase Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on June 20, 2024, for its annual meeting scheduled for August 5, 2024. The filing c
Inhibikase Therapeutics Announces 2024 Annual Meeting of Stockholders — Apr 26, 2024 Risk: low
Inhibikase Therapeutics, Inc. (IKT) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. The 2024 Annual Meeting of Stockholders for Inhibikase The

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX